Global tuberculosis (TB) Report 2024

Introduction to Tuberculosis (TB)

Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs (pulmonary TB), but it can also impact other parts of the body. It spreads through the air when an infected person coughs or sneezes. Despite being preventable and treatable, TB remains a leading cause of morbidity and mortality globally, particularly in low- and middle-income countries.
Key Statistics in the Global Tuberculosis Report 2024
The Global Tuberculosis Report 2024 provides an in-depth analysis of the current TB situation worldwide. Some of the key statistics and findings include:
  1. Global TB Incidence
    • The number of new and relapse TB cases in 2022 was approximately 10.6 million, with an estimated 1.6 million deaths.
    • TB incidence rates have shown a slight decline, but the progress is slower than anticipated due to various challenges such as the COVID-19 pandemic’s impact on TB detection and treatment.
  2. Drug-Resistant TB
    • The report highlights the rising threat of drug-resistant tuberculosis (DR-TB), which includes multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains.
    • Around 450,000 people developed MDR-TB in 2022, and 187,000 deaths occurred due to DR-TB.
  3. Treatment and Diagnosis
    • Despite significant improvements in diagnosis and treatment, the report points out that around one-quarter of TB cases remain undiagnosed or untreated.
    • The availability of new diagnostic tools such as molecular tests has improved early detection, but their reach is still limited, especially in resource-constrained settings.
  4. Impact of the COVID-19 Pandemic
    • The COVID-19 pandemic significantly disrupted TB diagnosis, treatment, and prevention efforts. The report indicates that the pandemic exacerbated challenges such as TB service interruptions, delayed diagnoses, and limited access to care, leading to setbacks in TB control efforts.
  5. Funding and Resource Gaps
    • Global investments in TB prevention, diagnosis, and treatment remain insufficient. The report estimates a funding gap of over $1 billion for 2024 to meet the global TB targets.

Challenges in Tackling Tuberculosis Globally

  1. Underdiagnosis and Undernotification

    • A major challenge in TB control is the underreporting of cases, particularly in low-resource settings. This is due to a combination of factors such as lack of healthcare infrastructure, inadequate access to diagnostic services, and stigma associated with TB.
  2. Drug Resistance

    • The rise of MDR-TB and XDR-TB is a growing concern, as these forms of TB are more difficult and expensive to treat. Limited access to second-line drugs and delays in treatment initiation increase the risk of transmission and mortality.
  3. Co-Infection with HIV

    • HIV and TB often occur together, with people living with HIV being at a higher risk of contracting TB. Co-infection complicates the management of both diseases, as HIV weakens the immune system and makes TB harder to diagnose and treat effectively.
  4. Stigma and Social Determinants of Health

    • TB is often associated with stigma, which may prevent people from seeking diagnosis and treatment. Moreover, poverty, poor nutrition, and congested living conditions are major social determinants that exacerbate TB transmission.
  5. Inadequate Health Systems

    • Many countries, especially in sub-Saharan Africa and South Asia, face weak health systems with limited access to quality care, making it challenging to diagnose and treat TB effectively.

Progress in Tuberculosis Control

Despite these challenges, the Global Tuberculosis Report 2024 also highlights several areas of progress:

  1. Improved Diagnostics

    • New diagnostic tools, such as GeneXpert MTB/RIF, have improved TB detection, particularly in high-burden countries. These tools can rapidly diagnose TB and detect drug resistance, leading to quicker treatment decisions.
  2. New Drug Regimens

    • The development of new drug regimens, such as Bedaquiline and Delamanid, has revolutionized the treatment of DR-TB. These drugs are more effective and have fewer side effects compared to older treatments.
  3. Global Commitment and Targets

    • The End TB Strategy, adopted by the World Health Assembly, aims to reduce TB deaths by 90% and cut TB incidence by 80% by 2030. Although progress is slow, countries are making efforts to achieve these targets, and international collaboration is improving.
  4. Innovative TB Vaccines

    • The development of new TB vaccines, such as the M72/AS01E vaccine, shows promise in preventing TB in high-risk populations. These vaccines could be a game-changer in the global fight against TB.
  5. Global Partnerships

    • Organizations like the Global Fund, Stop TB Partnership, and World Health Organization are playing critical roles in coordinating global efforts, providing funding, and supporting research and innovation in TB control.

Global and National TB Response Strategies

  1. WHO’s End TB Strategy

    • The End TB Strategy aims to reduce TB deaths by 90%, cut TB incidence by 80%, and eliminate catastrophic costs for families by 2030. This strategy includes comprehensive approaches such as early diagnosis, effective treatment, and improved access to healthcare.
  2. Country-Specific Efforts

    • India, which carries a quarter of the world’s TB burden, has made significant strides through initiatives such as the National TB Elimination Program (NTEP). In 2024, India is focusing on improving case detection, enhancing treatment regimens, and eliminating TB-related stigma. The TB Harega, Desh Jeetega campaign is an example of India’s commitment to ending TB.
  3. Community Engagement and Social Protection

    • Engaging communities and strengthening social protection programs can help reduce stigma and ensure that people adhere to TB treatment regimens. Community health workers play a vital role in early detection, awareness, and providing care in hard-to-reach areas.
  4. Increased Funding and Investment

    • The report emphasizes the need for increased funding to ensure TB programs can scale up. Countries need to allocate more resources for TB diagnosis, treatment, research, and healthcare infrastructure to reach the targets of the End TB Strategy.

India’s Role in the Global Tuberculosis Fight

  • India has the highest burden of TB cases in the world, with around 27% of the global incidence. As the largest contributor to global TB cases, India’s response is critical to achieving the targets set by the WHO End TB Strategy.

    1. National TB Elimination Program (NTEP)

      • India’s NTEP focuses on improving case detection, universal drug sensitivity testing, and ensuring the availability of effective treatment. The program is integrated with other health initiatives like the Ayushman Bharat and Pradhan Mantri TB Mukt Bharat Abhiyan.
    2. Private Sector Engagement

      • A significant proportion of TB patients in India seek treatment from the private sector. Integrating the private sector into the TB care system is a priority to ensure that all patients are diagnosed and treated according to national guidelines.
    3. Innovative Approaches

      • India has been investing in digital health solutions to track TB cases and treatment adherence. The Nikshay Arogya initiative provides financial support to TB patients to mitigate the economic burden of treatment.
    4. Research and Development

      • India is investing in TB research, including vaccine development, diagnostics, and new drug formulations. Indian researchers are actively participating in global TB research initiatives.

Conclusion

Tuberculosis remains a major global health challenge, but significant progress has been made in the fight against the disease. The Global Tuberculosis Report 2024 highlights the continued efforts required to reach the targets of the End TB Strategy, with a focus on overcoming challenges such as drug resistance, underdiagnosis, and inadequate funding.

For UPSC aspirants, understanding the complexities of TB, the strategies in place to combat it, and India’s role in the global response is crucial. As a pressing public health issue, TB is an important topic under the General Studies Paper II (Governance, Constitution, Polity, Social Justice and International relations) and General Studies Paper III (Science and Technology, Environment, and Development). By staying informed about global health issues like TB, aspirants can provide comprehensive, well-rounded answers in their exams and contribute to India’s efforts in ending TB by 2030.

Maximize the benefits of mock tests for IAS and KAS preparation with guidance from Amoghavarsha IAS Academy . For more details, visit https://amoghavarshaiaskas.in/.

Youtube: click here

Enroll Now !
Media & News
Similar Articles for UPSC Aspirants